GlassScriptPhysician profile
Michael Ryan Vaclaw
NPI 1942295308
$3,360.79
in general payments reported to CMS, 2019-2025
35 companies · $550 in 2025
The $550 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $262 · 2021: $327 · 2022: $487 · 2023: $659 · 2024: $550 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,758.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $760.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $322.25 | 2019-2025 | Veozah |
| Lilly USA, LLC | $295.57 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $288.91 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $283.12 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $246.91 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $230.49 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.24 | 2019-2024 | Ofev, Jardiance |
| Merck Sharp & Dohme LLC | $61.10 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $58.70 | 2019-2021 | |
| Abbott Laboratories | $50.93 | 2023 | Freestyle Libre 3 |
| Ultragenyx Pharmaceutical INC. | $48.31 | 2021-2022 | |
| Glaxosmithkline, LLC. | $43.51 | 2021-2023 | Arexvy, Shingrix |
| Organon LLC | $42.38 | 2021-2023 | Nexplanon |
| Exact Sciences Corporation | $37.95 | 2023-2024 | Cologuard Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $36.26 | 2020-2023 | |
| Dexcom, INC. | $35.34 | 2023-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $33.80 | 2020 | |
| Corium, LLC | $30.10 | 2023 | Azstarys |
| Allergan, INC. | $30.02 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $29.74 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.30 | 2022 | |
| Abiomed | $21.88 | 2024 | Impella |
| Antares Pharma, INC. | $20.42 | 2024 | Xyosted |
| Supernus Pharmaceuticals, INC. | $20.16 | 2023 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $19.79 | 2023 | Rexulti |
| Biogen, INC. | $18.43 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.88 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $15.16 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.07 | 2023 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $14.88 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.50 | 2025 | Caplyta |
| Sanofi Pasteur INC. | $13.90 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.64 | 2024 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $13.53 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Vaclaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.